Seeking Alpha

QualityStocks'  Instablog

QualityStocks
Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
QualityStocks
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • VistaGen Therapeutics, Inc. (VSTA) Highlights Drug Rescue Potential At Noble Financial Capital Markets' 9th Annual Equity Conference 0 comments
    Feb 12, 2014 10:27 AM | about stocks: VSTA

    VistaGen Therapeutics is a California-based biotechnology company that specializes in the application of human pluripotent stem cell (hPSC) technology for drug rescue, including predictive toxicology and drug metabolism screening. The company's hPSC technology platform, Human Clinical Trials in a Test Tube™, enables accessibility to the heart and liver safety profile of drug rescue variants and other new drug candidates with greater speed and precision than conventional nonclinical testing and technologies used in drug development. Harnessing this technology's unique power, VistaGen Therapeutics enables "drug rescue" of once-promising-but-now-backshelved drug candidates that have been discontinued by biotechnology or pharmaceutical companies prior to market approval due to unexpected heart or liver safety concerns.

    Recently, the company made an appearance at Noble Financial Capital Markets' 9th Annual Equity Conference. The conference took place Wednesday, January 22, 2014 to Thursday, January 23, 2014 at the Seminole Hard Rock Hotel in Hollywood, Florida. There, some 100 publicly held companies' corporate representatives showcased their companies' profiles, business strategies, and outlooks. Investment portfolio managers and equity analysts were on hand to analyze the representatives' presentations, ask questions, and get a good all-around sense of how each business offers growth potential.

    At the event, Mr. Shawn K. Singh, J.D., Chief Executive Officer of VistaGen Therapeutics, said that VistaGen Therapeutics is "changing the game" in the area of stem cell technology. Noting his experience of 22 years in the biotech space, Mr. Singh noted that 2014 will be the "breakout year" for the company.

    Having touched upon his executive experience, he then said that the company is "applying stem cell technology in ways [he] has not seen possible in the last couple of decades in this space." According to a Forbes article from February 2012, the sunk cost of drug development is huge, as the "average drug developed by a major pharmaceutical company costs at least $4 billion." Likewise, the failure of drug development was noted to be staggering and largely attributable to heart or liver toxicity, with over 50% of drug development efforts failing due to these medical concerns.

    Mr. Singh touched upon the efficacy of Human Clinical Trials in a Test Tube in combating these sunk cost risks, as the hPSC technology platform identifies failure potential early in a drug's development process before too many cost have been paid. In short, the technology lets pharmaceutical companies "bring human biology to the forefront of drug development", thereby letting them "change the game early" in their drug development stages. He then went on to discuss other key company focuses and goals for 2014.

    The entirety of Mr. Singh's presentation at the Noble conference can be found at: noble.mediasite.com/mediasite/Play/7b2df...-e3a1f13bc7fb

    For more information about VistaGen Therapeutics and its technologies, visit: www.vistagen.com

    QualityStocks provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.qualitystocks.net

    Stocks: VSTA
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.